40
Immuno Cancer Biotherapeutics raises indefinite capital under Reg D 506(b) in Delaware biotech startup
Company raise · Open-ended · CANTON, SD · Form D filed 2026-10-15
Immuno Cancer Biotherapeutics, a Delaware corporation incorporated in 2024, is raising an indefinite amount under Regulation D 506(b) exemption. The company has sold $75K to three investors as of October 9, 2026.
Note: New issuer on EDGAR; indefinite offering amount; minimal capital raised to date ($75K) suggests very early stage.
First raise on EDGARoperating_company
How this compares
- No earlier fund launch by this sponsor appears on EDGAR.
Computed from every Form D fund launch on EDGAR since late 2024, not sampled. Amounts are the stated offering size; indefinite offerings are excluded.
People on the filing
| James Robl | Executive Officer, Director |
| Stephen Collins | Director |
Signed by James Robl, Executive Chairman.
Why now — by persona
- Executive & technical recruiting:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- B2B software & services sales:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- Commercial banking / treasury:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- D&O and management-liability insurance:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- Outsourced accounting / CFO:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
Filing contact
The issuer's phone number and address from the filing are shown to subscribers. See plans.